Compare COGT & DUOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COGT | DUOL |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 6.3B |
| IPO Year | 2018 | 2021 |
| Metric | COGT | DUOL |
|---|---|---|
| Price | $34.67 | $146.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 18 |
| Target Price | $36.21 | ★ $176.69 |
| AVG Volume (30 Days) | ★ 1.8M | 1.3M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 355.85 |
| EPS | N/A | ★ 1.53 |
| Revenue | $7,871,000.00 | ★ $1,037,589,000.00 |
| Revenue This Year | N/A | $18.93 |
| Revenue Next Year | $1,733.58 | $14.02 |
| P/E Ratio | ★ N/A | $93.37 |
| Revenue Growth | N/A | ★ 38.71 |
| 52 Week Low | $11.61 | $87.89 |
| 52 Week High | $43.73 | $353.00 |
| Indicator | COGT | DUOL |
|---|---|---|
| Relative Strength Index (RSI) | 40.39 | 55.35 |
| Support Level | $35.27 | $142.10 |
| Resistance Level | $35.95 | $151.00 |
| Average True Range (ATR) | 1.38 | 6.81 |
| MACD | -0.29 | 0.03 |
| Stochastic Oscillator | 13.89 | 64.94 |
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Duolingo Inc is a technology company that develops a mobile learning platform to learn languages. Its products are powered by sophisticated data analytics and artificial intelligence and delivered with class art, animation, and design to make it easier for learners to stay motivated, master new material, and achieve their learning goals. Its solutions include the Duolingo Language Learning App, Super Duolingo, Duolingo English Test: AI-Driven Language Assessment, Duolingo For Schools, Duolingo ABC, and Duolingo Math. It has four predominant sources of revenue: time-based subscriptions, in-app advertising placement by third parties, the Duolingo English Test, and In-App purchases. Geographically, the company generates revenue from its customers in the United States and other markets.